On August 7, 2025, HistoSonics, the developer of the Edison® Histotripsy System and a pioneer in non-invasive, focused ultrasound therapies, announced a management-led majority stake acquisition valued at approximately $2.25 billion. The transaction was backed by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management, and other new and existing investors. Wilson Sonsini advised HistoSonics’ existing major shareholders in connection with the transaction.

The transaction positions HistoSonics for accelerated growth of its Edison® Histotripsy System across new clinical indications and global markets.  The company will continue to be led by President and CEO Mike Blue, who will also assume the role of Chairman of the Board.

With FDA De Novo clearance secured in 2023, HistoSonics’ proprietary histotripsy platform is currently being used at over 50 U.S. medical centers to treat liver tumors, with additional trials underway for kidney and pancreas indications. The Edison® system has been used to treat more than 2,000 patients to date, with another 50 installations planned by year-end.

The Wilson Sonsini team advising HistoSonics’ shareholders was led by Michael Danaher and Philip Oettinger and included Jonathan Zhu, Mark Holloway, Kimberley Biagioli, and Joshua Gruenspecht.

For more information, please see HistoSonics’ news release here. Additional coverage can be found in The Wall Street Journal, Crain’s, and PEHub.